# Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

> **NCT00957268** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 46 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Alogliptin

## Key facts

- **NCT ID:** NCT00957268
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2015-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00957268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00957268, "Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00957268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*